The FLIP-1 Study: Vaginal Lactobacillus Supplementation in Women at High Risk of Preterm Birth

NCT03992534 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-05-28

No results posted yet for this study

Summary

Preterm birth (PTB) is the primary cause of infant death worldwide. It has been shown that a vaginal microbiota deplete in Lactobacillus species is a risk factor for preterm labour. Conversely a vaginal microbiota dominated by Lactobacillus crispatus appears to be protective for these adverse outcomes. A wide range of 'over the counter' Lactobacillus spp. containing products targeted at 'vaginal health' and formulated for vaginal administration are available, but most of them do not contain vaginal species of Lactobacillus. The primary aim of this study is to determine whether vaginal supplementation with L. crispatus CTV-05 is associated with colonisation.

Conditions

  • Preterm Labor
  • Preterm Birth
  • Preterm Premature Rupture of Membrane
  • Cervical Incompetence
  • Miscarriage in Second Trimester
  • Miscarriage in Third Trimester

Interventions

COMBINATION_PRODUCT

LACTIN-V

Vaginal supplementation with L. crispatus CTV-05.

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    collaborator OTHER
  • Imperial College London

    lead OTHER

Principal Investigators

  • Phillip Bennett, BSc PhD MD · Imperial College London

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2021-10-01
Completion
2021-10-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03992534 on ClinicalTrials.gov